Paper · 41365129
Radiotherapy in the management of PDAC, from past to present.
Dardare J and 8 others. Transl Oncol, 2026. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Radiotherapy in the management of PDAC, from past to present. Papers, record 41365129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41365129
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References75
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21,499,862 | Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. | Ann Surg Oncol | 2011 | https://conductscience.org/library/papers/21499862 | PubMed |
| 2 | 37,678,671 | Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2023 | https://conductscience.org/library/papers/37678671 | PubMed |
| 3 | 4,015,380 | Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. | Arch Surg | 1985 | https://conductscience.org/library/papers/4015380 | PubMed |
| 4 | 32,105,518 | Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/32105518 | PubMed |
| 5 | 33,665,480 | Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. | Adv Radiat Oncol | 2021 | https://conductscience.org/library/papers/33665480 | PubMed |
| 6 | 23,265,573 | Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study. | Int J Radiat Oncol Biol Phys | 2013 | https://conductscience.org/library/papers/23265573 | PubMed |
| 7 | 37,643,780 | Identification of Biomarkers Related to the Efficacy of Radiotherapy in Pancreatic Cancer. | Cancer Genomics Proteomics | 2023 | https://conductscience.org/library/papers/37643780 | PubMed |
| 8 | 22,483,737 | Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. | Int J Radiat Oncol Biol Phys | 2012 | https://conductscience.org/library/papers/22483737 | PubMed |
| 9 | 24,355,035 | Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. | Gastroenterology | 2014 | https://conductscience.org/library/papers/24355035 | PubMed |
| 10 | 36,048,453 | Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. | JAMA Oncol | 2022 | https://conductscience.org/library/papers/36048453 | PubMed |
1 to 10 of 75
See all 75 referencesCited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,919,966 | Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. | Nat Med | 2026 | https://conductscience.org/library/papers/42919966 | PubMed |
| 42,724,545 | Global hotspots and trends of stereotactic radiotherapy for pancreatic cancer: a bibliometric analysis and visual analysis from 2015 to 2025. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724545 | PubMed |
| 42,592,360 | Exploring the role of immunotherapy and radiotherapy in the adjuvant landscape of resected pancreatic cancer. | Transl Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42592360 | PubMed |
| 42,545,416 | Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis of Randomised Controlled Trials. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42545416 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41365129
GET https://conductscience.org/api/papers/v1/41365129/references?page=2